Robyn Karnauskas, a biotechnology analyst at Deutsche Bank who has a buy rating on Dendreon shares, argued in her initiation note earlier this month that the Medicare process could be much faster than investors expect.
FORBES: Medicare Meeting A Good Sign For Dendreon